Clinical efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma and nasal polyposis: pooled analysis of the SIROCCO and CALIMA trials

Abstract:

Methods This was a post-hoc pooled analysis of the Phase III SIROCCO (48 weeks; NCT01928771; Lancet. 2016; 388: 2115–27) and CALIMA (56 weeks; NCT01914757; Lancet. 2016; 388: 2128–41) trials. Patients aged≥ 12 years receiving high-dosage inhaled corticosteroids/long-acting β 2-agonists with baseline blood eosinophils≥ 300 cells/µL received benralizumab 30 mg subcutaneously every 8 weeks (Q8W; n= 506) or placebo (n= 515). Results Patients with NP (NP+) generally had greater mean blood eosinophil counts (Q8W: 668 cells/µL; placebo: 749 cells/µL) than patients without NP (NP−; Q8W: 606 cells/µL; placebo: 597 cells/µL). Baseline maintenance oral corticosteroid use was also greater for NP+(Q8W: 31.3%; placebo: 21.4%) than for NP−(Q8W: 10.5%; placebo: 10.1%). Placebo exacerbation rates during treatment were 1.27 (n= 515), 1.74 (n= 117), and 1.13 (n= 398) for the overall, NP+, and …

Año de publicación:

2019

Keywords:

Fuente:

google